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INTRODUCTION: 
Solid lip id nanoparticles were firstly investigated in 1990 
by Muller and Gasco. These submicron colloidal particles 
composed of physiological lipids and dispersed in aqueous 
surfactant solution
1
. They are new generation sub-micron 
sized lipid emulsion of 50-1000 nm in size and in which  
liquid lipid is substituted by solid lip id. They can carry 
both lipophilic and hydrophilic  drugs.SLNs provide unique 
properties such as least size, large surface area, high drug 
loading and the interaction of phases at the interface and 
are attractive for their potential to improve performance of 
pharmaceuticals
2
. Solid lipid nanoparticles have many 
advantages like low cost of ingredients, ease of preparation 
and scale-up etc
3
. SLNs are prepared by many methods 
such as High pressure homogenization, Ultrasonication 
Technique, Solvent evaporation method, Solvent injection 
method (Solvent displacement method), Solvent 
emulsification-diffusion method, Supercritical fluid  
method, Microemulsion based method, Spray dry ing 
method, Double emulsion method and Precipitation 
technique
4,5,6
.The oral route is the most preferred route for 
drug administration due to its convenience and good 
patient compliance. Drug solubility is a major challenge 
now days for hydrophobic drugs, 40% of all newly  
developed drugs are poorly soluble or insoluble in water
7
. 
There were much more research has done into methods for 
improving the solubility and dissolution rate of drugs in 
order to increase the bioavailability in case of hydrophobic 
drugs. Aceclofenac (2-[(2, 6 dich lorophenyl) amine] 
phenylacetoxyacetic acid) is an orally effective non-
steroidal anti- in flammatory drug (NSAID) of the phenyl 
acetic acid group. It possesses anti-inflammatory, 
analgesic and anti-pyretic activity
8,9
. The solubility of 
aceclofenac in water is very poor and thus it shows poor 
bioavailability after o ral admin istration
10,11
. There are 
hardly any reports on the preparation of solid lipid  
nanoparticles of aceclofenac and solubility enhancements 
of aceclofenac by solvent injection method. Solvent 
injection method is a straight forward method with no need 
of sophisticated equipment to manufacture lipid  
nanoparticles. The particle size can be influenced and 
controlled by variation of processing parameters like 
injected solvent, lipid concentration, injected amount and 
viscosity in this method.Hence the objective of the present 
study is to prepare and evaluate solid lip id nanoparticles of 
aceclofenac using solvent injection method
12,13
. 
MATERIALS: 
Aceclofenac was a gift sample of Mankind 
Pharmaceuticals, Dehradun, India. Po loxamer 188 was 
gifted by Alcon Laboratories Pvt. Ltd, Bangalore, India.  
Glycery l behenate (Compritol 888 ATO) and dialysis 
membrane wereprocured from HiMedia Laboratories Pvt. 
Ltd, Mumbai, India. Isopropyl alcohol andTween 80 were 
procured from Rankem, Okhla Industrial Area, New Delh i, 
India. 
METHODOLOGY:  
Solid lip id nanoparticles of aceclofenac were prepared by 
using solvent injection method
12,13
. Aceclofenac (100 mg) 
and specified amount of Glyceryl behenate was dissolved 
in specified quantity of isopropyl alcohol (IPA) (boiling 
point 81
º
C to 83
º
C) with heating at melt ing temperature of 
solid lipid. Glycery l behenate is soluble in IPA; however, 
it requires some heat for ease of solubilizat ion. The 
resulting solution was rapidly injected into the 10 ml of 
aqueous phase containing specified amount of Poloxamer 
188 that was continuously stirred at 400 rpm for 30 min on 
a magnetic stirrer; 0.1N HCl (4 ml) was added to the 
dispersion to decrease the pH around 1.5 - 2 to cause the 
aggregation of SLNs for the ease of separation.The 
resulted dispersion was then filtered with a filter paper in 
order to remove any excess lipid. Thereafter, the 
dispersion was centrifuged to 4,000 rpm for 30 min at in  
REMI cooling centrifuge, and aggregates were 
resuspended to 10 ml double distilled water containing 4% 
Poloxamer 188 (by weight) as stabilizer with stirr ing at 
1,000 rpm for 10 min. 
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CHARACTERIZATION AND EVALUATION OF 
SLNs: 
Particle size: 
For the measurement of part icle size photon correlation 
spectroscopy (PCS) and laser diffraction (LD) are 
important techniques.Thesurface morphology of SLNs was 
characterized by Scanning electron microscopy (SEM) 
which was conducted to characterize the surface 
morphology of the SLNs. The samples were mounted on 
alumina stubs using double adhesive tape, coated with gold 
in Sputter coater- Polaron SC7640. Then the sample was  
observed in SEM at an acceleration voltage of 20KV and a 
magnificat ion of different X i.e. from 9X to 32X.  
 
Figure 1: S EM analysis of SLNs of aceclofenac at 
magnification 9.57 KX 
 
Figure 2: S EM analysis of SLNs of aceclofenac at 
magnification 32.85 KX 
 
Fourier transformed infrared (FT-IR) spectroscopic 
analysis: 
About 1–2 mg of sample of was mixed with dry potassium 
bromide and the samples were examined at transmission 
mode over wave number range of 4000 to 400 cm
-1
. FT-IR 
studies were carried out on pureGlyceryl behenate and 
Aceclofenac as bulk materials and SLNs loaded with 
Aceclofenac. 
Entrapment efficiency
 14
: 
The entrapment efficiencies of prepared systems were 
determined by measuring the concentration of free drug in 
the dispersion medium. The unentrapped Aceclofenac was 
determined by adding 0.1 ml of the nanosuspension to 9.9 
ml ethanol (95%); the obtained suspension was centrifuged 
for 45 min at 6,000 rpm. The supernatant was separated 
and filtered through filter paper 0.2-μm filter. The filtrate 
was diluted using ethanol and measured 
spectrophotometrically (Systronics 2203Smart, India.). 
The amount of free drug was detected in the filtrate and the 
amount of incorporated drug was determined as a result of 
the initial drug minus the free drug. The entrapment 
efficiency was calcu lated using the following equation: 
                                  WInital Drug – WFree Drug     × 100 
              % EE   =             
                                                W  Initial Drug                                      
 
Where “W initialdrug” is the mass of initial drug used and the 
“Wfree drug” is the mass of free drug detected in the 
supernatant after centrifugation of the aqueous dispersion. 
The entrapment efficiency of the optimized formulations 
(F6, F7 and F8) was found to be maximum among all the 
formulat ions. And F7 has the most maximum entrapment 
of drug in the SLNs i.e. 90% which is resulted due to the 
high concentration of lipid and low concentration of 
poloxamer used in the formulation.  
In-vi tro drug release
 15
: 
In-vitro drug release of selected SLNs was performed by 
dialysis bag diffusion technique. Solid lipid  
nanosuspension equivalent to 5 mg of aceclofenac was 
filled in d ialysis bag (Dialysis Membrane-  12–14 k Da, 
pore size 2.4 nm) and immersed in receptor compartment 
containing 150 ml of phosphate buffer pH 6.8 stirred at 
100 rpm at a temperature of 37 ± 0.5°C. Five millilitre of 
aliquots were withdrawnat regular t ime intervals (4, 8, 12, 
24, 28, 32, 36, 48, 52, 55 hrs.) and rep lenishment of 
receptor compartment with same volume of fresh dialyzing 
medium was done and the samples were analysed for % 
cumulat ive drug release at 55
th
 hr. Among the ten 
formulat ions F6, F7 and F8 were selected as the optimized  
formulat ions and F7 is considered as the best one. In these 
optimized formulations low amount of poloxamer 188 and 
slightly high amount of lipid glyceryl behenate was used. 
And the solvent, Isopropyl alcohol, was also used in the 
optimized quantity. 
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Figure 3: FTIR spectra of aceclofenac, glyceryl behenate and formulation.  
 
Figure 4: %  Drug entrapment efficiency of formulation F1 to F10  
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Figure 5: %  Drug Release of formulation F1  to F10  
 
RES ULT AND DISCUSSION: 
In the present work an attempt was made to prepare solid 
lip id nanoparticles of aceclofenac using glyceryl behenate 
as solid lipid, po loxamer 188 as surfactant and isopropyl 
alcohol as solvent. The FTIR spectroscopy showed 
positive results for the API. The IR spectrum was 
performed in percentage transmission (%T) versus wave 
number. The melt ing point of aceclofenac was determined 
by melt ing point apparatus, which was found to be 145
0
C-
155
0
C and compared to the literature value 149
0
C-153
0
C. 
Drug compatibility was performed by Cartension method 
and FT-IR spectroscopic studies which showed that 
excip ients were compatible with API. The SLNs were 
prepared using solvent injection method. Ten formulations 
were prepared successfully which exhibit the particle size 
of the prepared formulat ions was found in the range 
between 226.9 nm to 451.2 nm. Surface charge of the 
formulat ions was found to be -12.89 kV to -35.22 kV. 
Entrapment efficiency of the formulations was found to be 
from 55% to 90%. Aceclofenac loaded SLNs show in-vitro  
percentage drug release from 57.12% to 90.22%.  
CONCLUSION: 
Aceclofenac solid lipid nanoparticles are prepared by solvent 
injection method using glyceryl behenate as solid lipid core and 
poloxamer 188 as surfactant. Effect of the process parameters 
such as particle size, entrapment efficiency and drug release from 
SLNs were studied.The results indicated that SLNs which have 
least particle size can release properly from nanoparticles. FT-IR 
spectra studies indicated that there was no interaction of lipid and 
poloxamer with drug. Further studies can be performed as in-vivo 
drug release in animals in future.  
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